PLAUR and prostate carcinoma: This conclusion was confirmed in prostate carcinoma (PC3) cells which constitutively express uPAR; in fact, uPAR depletion by a uPAR-specific siRNA or uPAR blocking by a uPAR-specific antibody completely impaired PC3 cell migration toward serum.